# Study of Intravenous Telisotuzumab Vedotin in Combination Osimertinib or Standard of Care Chemotherapy to Assess Change in Disease Activity in Adult Participants With Non-Small Cell Lung Cancer That Has a Mutation in the Epidermal Growth Factor Receptor Gene and That Overexpresses the c-Met Protein

> **NCT06093503** · PHASE3 · WITHDRAWN · sponsor: **AbbVie**

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Telisotuzumab Vedotin
- **DRUG:** Osimertinib
- **DRUG:** Cisplatin
- **DRUG:** Carboplatin
- **DRUG:** Pemetrexed

## Key facts

- **NCT ID:** NCT06093503
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-05-31
- **Primary completion:** 2028-04-11
- **Final completion:** 2028-04-11
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Strategic considerations
- **Last updated:** 2024-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06093503

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06093503, "Study of Intravenous Telisotuzumab Vedotin in Combination Osimertinib or Standard of Care Chemotherapy to Assess Change in Disease Activity in Adult Participants With Non-Small Cell Lung Cancer That Has a Mutation in the Epidermal Growth Factor Receptor Gene and That Overexpresses the c-Met Protein". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06093503. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*